1.13
-0.08(-6.61%)
Currency In USD
| Previous Close | 1.21 |
| Open | 1.17 |
| Day High | 1.24 |
| Day Low | 1.1 |
| 52-Week High | 2.84 |
| 52-Week Low | 0.61 |
| Volume | 183,156 |
| Average Volume | 180,119 |
| Market Cap | 62.36M |
| PE | -0.69 |
| EPS | -1.64 |
| Moving Average 50 Days | 0.97 |
| Moving Average 200 Days | 0.93 |
| Change | -0.08 |
If you invested $1000 in Prelude Therapeutics Incorporated (PRLD) since IPO date, it would be worth $43.13 as of September 13, 2025 at a share price of $1.13. Whereas If you bought $1000 worth of Prelude Therapeutics Incorporated (PRLD) shares 3 years ago, it would be worth $144.13 as of September 13, 2025 at a share price of $1.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
GlobeNewswire Inc.
Jun 02, 2025 11:30 AM GMT
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
GlobeNewswire Inc.
May 01, 2025 11:30 AM GMT
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference t
Prelude Announces Presentations at 2025 AACR Annual Meeting
GlobeNewswire Inc.
Apr 25, 2025 8:05 PM GMT
Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders,